Holen Sie sich die Stockscreener-App
0.392
10.91%
-0.048
Schlusskurs vom Vortag:
$0.44
Offen:
$0.47
24-Stunden-Volumen:
1.49M
Relative Volume:
1.38
Marktkapitalisierung:
$14.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.68M
KGV:
-0.0268
EPS:
-14.6193
Netto-Cashflow:
$-12.91M
1W Leistung:
-8.84%
1M Leistung:
+25.44%
6M Leistung:
-51.11%
1J Leistung:
-86.44%
1-Tages-Spanne:
$0.3852
$0.47
1-Wochen-Bereich:
$0.3852
$0.4888
52-Wochen-Spanne:
$0.261
$3.85
Gt Biopharma Inc Stock (GTBP) Company Profile
Firmenname
Gt Biopharma Inc
Sektor
Branche
Telefon
(800) 304-9888
Adresse
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.40 | 2.93B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
7.50 | 432.93M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.13 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.29 | 288.61M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.54 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | ROTH MKM | Buy |
| 2021-05-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-13 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-17 | Eingeleitet | ROTH Capital | Buy |
Gt Biopharma Inc Aktie (GTBP) Neueste Nachrichten
GT Biopharma, Inc. 8-K Filing: Nasdaq Compliance, Company Details & Key Disclosures (May 20, 2026) 10 - Minichart
GT Biopharma receives 180-day extension from Nasdaq to meet minimum bid price - Investing.com
GT Biopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq grants GT Biopharma (NASDAQ: GTBP) 180-day minimum bid reprieve - Stock Titan
GTBP Stock Chart | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
GT Biopharma Edges Higher, Testing Key Resistance at $0.45Community Watchlist Picks - Newser
GT Biopharma Q1 2026 Earnings: Wider-Than-Expected Loss Amid Strategic Pipeline UpdatesCommunity Exit Signals - Newser
GT Biopharma Inc stock (US36254L1098): new B7-H3 TriKE enters the clinic and puts NK cell engagers i - AD HOC NEWS
Exclusive: GT Biopharma begins testing of lead solid tumor drug candidate across multiple cancer types - MSN
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic - Sahm
Why Is GT Biopharma, Inc. (GTBP.PA) Stock Down Today? - Meyka
GT Biopharma Inc stock (US36254L1098): clinical pipeline and stock under pressure after recent finan - AD HOC NEWS
Key facts: GT Biopharma Q1 Loss $2.83M; Nasdaq Listing at Risk - TradingView
GT Biopharma, Inc. Q1 2026 Financial Results: Quarterly Report, Financial Statements, and Key Disclosures - Minichart
GTBP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GT Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
GT Biopharma Reports First Quarter 2026 Financial Results - The Manila Times
GT Biopharma, Inc. 1Q 2026: Net loss $(2.83M), Revenue $0— 10-Q Summary - TradingView
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] GT Biopharma, Inc. Quarterly Earnings Report - Stock Titan
GTBP Q1'26 Earnings: EPS estimate is (0.08) USD - TradingView
First Patient Dosed in Phase 1 Trial Marks Expansion of NK Cell Engager Platform Into Solid Tumors - Baystreet.ca
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies - GlobeNewswire Inc.
GT Biopharma stock (US36254L1098): First patient dosed in solid tumor trial - AD HOC NEWS
GT Biopharma Inc - Menafn.com
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology - Toronto Star
GT Biopharma announces first patient dosed in phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors - marketscreener.com
GT Biopharma doses first patient in solid tumor trial By Investing.com - Investing.com Australia
GT Biopharma doses first patient in solid tumor trial - Investing.com India
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors - The Manila Times
GT Biopharma Announces First Patient Dosed in Phase 1 Trial - GlobeNewswire
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types - Benzinga
[EFFECT] GT Biopharma, Inc. SEC Filing - Stock Titan
9.72M GT Biopharma shares registered for resale (NASDAQ: GTBP) - Stock Titan
MSN Money - MSN
TradingKey - TradingKey
| Fierce Healthcare - Fierce Healthcare
GT Biopharma | UPLOAD: Others - Moomoo
GT Biopharma Inc stock (US36254L1098): FDA clears IND for NK cell therapy GTB-5550 in solid tumors - AD HOC NEWS
The critical factors shaping GT Biopharma (GTBP) future (Softens) 2026-05-08Large Cap Trends - Newser
GT Biopharma (NASDAQ: GTBP) registers 9.7M shares for investor resale - Stock Titan
Anthony Cataldo Stole $3.2M From GT Biopharma to Fund His Beverly Hills Mansion - hannahhowell.com
GTBP Stock Price, Quote & Chart | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
Replays from RedChip's Biotech Investor Conference Now Available - ChartMill
GT Biopharma (GTBP) Stock All or None (-1.58%) 2026-04-20Social Trading Insights - Newser
GTBP | GT Biopharma Inc. Common Insider Trading - Quiver Quantitative
GT Biopharma (GTBP) Stock: Volatility Risk (-0.26%) 2026-04-15Income Investing - Newser
Finanzdaten der Gt Biopharma Inc-Aktie (GTBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):